KEQU

Shares of Kewaunee Scientific Corporation KEQU have declined 3.4% since reporting results for the fourth quarter of fiscal 2026. This compares with the S&P 500 index’s 1.8% fall over the same time frame. Over the past month, the stock has lost 12.1% compared with the S&P 500’s 3.8% decline. Notably, the company’s shares have underperformed the broader market over both periods following the earnings release. Kewaunee Scientific reported fourth-quarter fiscal 2026 sales of $71.4 million, down 7.5% from $77.1 million a year earlier. Net earnings attributable to the company fell to $3.4 million from $4.9 million in the prior-year quarter, while diluted earnings per share declined to $1.13 from $1.63. Pre-tax earnings dropped to $4.8 million from $7.1 million, and quarterly EBITDA decreased to $6.5 million from $9.7 million. For the full fiscal year, however, revenues increased 17.3% to $282 million from $240.5 million. Net earnings declined to $9.6 million from $11.4 million, while diluted EPS decreased to $3.22 from $3.83. Annual EBITDA improved to $22.4 million from $21.6 million despite lower earnings, reflecting continued operating cash generation. Kewaunee Scientific Corporation price-consensus-eps-surprise-chart | Kewaunee Scientific Corporation Quote Performance varied across business segments during the quarter. The renamed Lab Products Group (“LPG”) generated sales of $54.4 million, down 2% year over year from $55.5 million. Segment net earnings declined to $3.5 million from $5.1 million, while EBITDA fell to $6.7 million from $8.8 million as lower manufacturing volumes in the laboratory construction business reflected continued volatility in project delivery schedules. The company said that it continued adjusting production schedules while focusing on productivity and cost management. The International segment recorded a steeper decline, with sales falling 21.3% to $17 million from $21.7 million. Segment net earnings slipped to $1.5 million from $1.6 million, while EBITDA declined to $2.1 million from $2.4 million. Management attributed the weaker performance primarily to shipment timing for Middle East projects, wherein deliveries continued to be affected by regional geopolitical disruptions. On a full-year basis, LPG revenues rose 19.8% to $214.9 million, while International sales increased 9.9% to $67.1 million. International profitability strengthe...

Kewaunee Scientific (KEQU) reported fiscal Q4 adjusted earnings late Tuesday of $1.14 per diluted sh

STATESVILLE, N.C., June 23, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its fiscal year and fourth quarter ended April 30, 2026. Fiscal Year 2026 Full Year Results Fiscal year 2026 was highlighted by strong revenue, continued progress integrating Nu Aire, and significant balance sheet improvement, despite a challenging operating environment. Sales during fiscal year 2026 were $281,999,000, an increase of 17.3% compared to sales of $240,472,000 from the prior year. Pre-tax earnings for the fiscal year were $13,733,000 compared to pre-tax earnings of $14,785,000 for the prior year. Net earnings for the fiscal year were $9,618,000, compared to net earnings of $11,405,000 for the prior year. Diluted earnings per share was $3.22, as compared to diluted earnings per share of $3.83 in the prior fiscal year. EBITDA1 for the fiscal year was $22,425,000, compared to $21,613,000 for the prior fiscal year. During fiscal year 2026, the Company renamed its Domestic reportable segment to Lab Products Group ("LPG") to better align with the segment's expanded business activities, organizational structure, and strategic direction. The segment name change had no impact on the composition of the Company's reportable segments or on previously reported financial position, results of operations, cash flows, or segment operating results. Fiscal Year Segment Results and Discussion: Lab Products Group Segment - LPG sales for the fiscal year were $214,886,000, an increase of 19.8% from sales of $179,398,000 in the prior year. LPG segment net earnings were $14,156,000 compared to $15,370,000 in the prior fiscal year. LPG segment EBITDA was $25,059,000 compared to $25,580,000 for the prior year. Lab Products Group segment results for fiscal year 2026 reflected solid execution and the perseverance of the Company's expanded domestic platform. The laboratory construction portion of the business faced challenging market conditions throughout the year, including volatility in project delivery timelines, lower manufacturing volumes during certain periods, higher input costs, and tariff-related cost pressure. These headwinds were partially mitigated by the team's continued productivity improvements, disciplined cost controls, proactive production scheduling, and further enhancement of the Company's strong operating foundation. The addition of...

STATESVILLE, N.C., June 10, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release financial results for its fourth quarter and fiscal year ended April 30, 2026 on Tuesday, June 23, 2026 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, Spain, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China. Learn more at the companies' websites, located at http://www.kewaunee.com and http://www.nuaire.com/. This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these word...

Shares of Kewaunee Scientific Corporation KEQU have declined 17.5% since reporting results for the third quarter of fiscal 2026, underperforming the S&P 500 index’s 2.2% fall over the same period. Over the past month, the stock has lost 15.7% compared with a 3.4% dip in the broader index, indicating a sharper negative market reaction to the company’s recent performance. Kewaunee reported mixed financial results for the fiscal third quarter ended Jan. 31, 2026. Net sales rose 3.3% year over year to $69.4 million from $67.2 million, reflecting modest top-line growth. However, profitability weakened significantly. Net earnings attributable to the company dropped roughly 49% to $0.7 million from $1.35 million in the prior-year period. Diluted earnings per share fell to 23 cents from 45 cents a year ago. While pre-tax earnings increased 25.8% to $1.6 million, the decline in net income suggests the impacts of higher taxes and non-controlling interests during the quarter. Kewaunee Scientific Corporation price-consensus-eps-surprise-chart | Kewaunee Scientific Corporation Quote Performance across segments was uneven. The domestic segment, which remains the largest contributor, reported sales of $51 million, down 2% year over year. Segment net earnings declined to $2.29 million from $2.88 million, with EBITDA also falling to $4.1 million from $5.2 million. The decline was attributed to lower manufacturing volumes, particularly in the laboratory construction portion of the business. In contrast, the international segment delivered strong growth. Sales increased 21.4% to $18.4 million, while net earnings surged to $1.26 million from $0.48 million. EBITDA nearly tripled to $2 million, driven primarily by higher billings in the Indian market. Order backlog, an important indicator of future revenues, stood at $183.2 million at the quarter-end, down from $221.6 million a year earlier and $214.6 million at the start of the fiscal year, signaling some softening in demand visibility. Management highlighted several external and internal factors shaping the quarterly performance. CEO Thomas D. Hull III noted that the third quarter is typically the company’s weakest due to seasonal effects, including holiday-related slowdowns and reduced construction activity during winter months. These cyclical factors were compounded by geopolitical and economic uncertainty, as well as volatil...

STATESVILLE, N.C., March 11, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its third quarter ended January 31, 2026. Fiscal Year 2026 Third Quarter Results: Sales during the third quarter of fiscal year 2026 were $69,399,000, an increase of 3.3% compared to sales of $67,167,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,604,000 compared to $1,275,000 for the prior year quarter, an increase of 25.8%. Net earnings were $692,000 compared to net earnings of $1,354,000 for the prior year quarter. EBITDA1 for the quarter was $3,795,000 compared to $3,734,000 for the prior year quarter. Diluted earnings per share were $0.23 compared to diluted earnings per share of $0.45 in the prior year quarter. The Company's order backlog was $183.2 million on January 31, 2026, as compared to $221.6 million on January 31, 2025, and $214.6 million on April 30, 2025. Domestic Segment - Domestic sales for the quarter were $50,953,000, a decrease of 2.0% from sales of $51,976,000 in the prior year quarter. Domestic segment net earnings were $2,290,000 compared to $2,876,000 in the prior year quarter. Domestic segment EBITDA was $4,096,000 compared to $5,249,000 for the prior year quarter. Segment profitability was impacted during the period by lower manufacturing volumes across the laboratory construction portion of the business. International Segment - International sales for the quarter were $18,446,000, an increase of 21.4% from sales of $15,191,000 in the prior year quarter. International segment net earnings were $1,256,000 compared to $476,000 in the prior year quarter. International segment EBITDA was $1,963,000 compared to $760,000 for the prior year quarter. International profitability increased when compared to the prior year period due to higher billings, principally in the Indian market. Corporate Segment – Corporate segment pre-tax net loss was $3,059,000 for the quarter, as compared to a pre-tax net loss of $3,025,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($2,264,000) compared to corporate segment EBITDA of ($2,275,000) for the prior year quarter. Corporate segment EBITDA remained relatively flat as the Company continues to make strategic investments in people, processes, and technology to further build out its Corporate platform and support continued...

Kewaunee Scientific (KEQU) reported fiscal Q3 adjusted earnings late Wednesday of $0.28 per diluted

STATESVILLE, N.C., Feb. 25, 2026 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release its third quarter fiscal year 2026 financial results on Wednesday, March 11, 2026 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China. Learn more at the companies' websites, located at http://www.kewaunee.com and http://www.nuaire.com/. This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intende...

Shares of Kewaunee Scientific Corporation KEQU have declined 1.3% since reporting results for the second quarter of fiscal 2026. This compares with the S&P 500 index’s 0.7% return over the same time frame. Over the past month, the stock has declined 4.5% against the S&P 500’s 3% growth. For the quarter ended Oct. 31, 2025, Kewaunee reported net sales of $70.1 million, representing a 46.8% increase from $47.8 million in the year-ago period. Despite the sharp rise in revenues, profitability declined year over year. Net earnings attributable to Kewaunee were $2.4 million, down from $3 million a year earlier, while diluted earnings per share fell to 82 cents from $1.01. Pre-tax earnings declined 12.2% year over year to $3.5 million. EBITDA, a non-GAAP measure, increased to $5.8 million from $4.9 million in the prior-year quarter, reflecting improved operating scale and contributions from acquisitions despite margin pressure. Kewaunee Scientific Corporation price-consensus-eps-surprise-chart | Kewaunee Scientific Corporation Quote Order backlog stood at $192.9 million as of Oct. 31, 2025, compared with $184.4 million a year earlier, though it declined sequentially from $214.6 million at the end of fiscal 2025. The backlog remains near historically high levels, particularly within the Domestic segment. On the balance sheet, total cash on hand was $13.7 million, down from $17.2 million at April 30, 2025, while working capital improved year over year to $67.8 million from $60 million. Long-term debt declined to $58.2 million from $60.7 million at the fiscal year-end, and the company’s debt-to-equity ratio improved to 0.88-to-1 from 0.99-to-1, signaling gradual balance-sheet strengthening in the quarter. Segmental performance was mixed. Domestic sales increased 51.7% year over year to $55.2 million, driven partly by the inclusion of Nu Aire, Inc., which delivered strong quarterly results. However, the domestic segment’s net earnings declined to $3.6 million from $4.5 million a year earlier due to lower manufacturing volumes in the laboratory construction portion of the business. International sales rose 31% year over year to $14.9 million, supported by the continued delivery of large projects booked in prior periods. International segment net earnings improved to $0.6 million from $0.4 million, and segment EBITDA increased accordingly. Management emphasized that proj...

Kewaunee Scientific (KEQU) reported fiscal Q2 earnings late Wednesday of $0.82 per diluted share, do

STATESVILLE, N.C., Dec. 10, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its second quarter ended October 31, 2025. Fiscal Year 2026 Second Quarter Results: Sales during the second quarter of fiscal year 2026 were $70,096,000, an increase of 46.8% compared to sales of $47,764,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,453,000 compared to $3,931,000 for the prior year quarter, a decrease of 12.2%. Net earnings were $2,445,000 compared to net earnings of $3,008,000 for the prior year quarter. EBITDA1 for the quarter was $5,790,000 compared to $4,883,000 for the prior year quarter. Diluted earnings per share were $0.82 compared to diluted earnings per share of $1.01 in the prior year quarter. The Company's order backlog was $192.9 million on October 31, 2025, as compared to $184.4 million on October 31, 2024, and $214.6 million on April 30, 2025. Domestic Segment - Domestic sales for the quarter were $55,224,000, an increase of 51.7% from sales of $36,409,000 in the prior year quarter. Domestic segment net earnings were $3,597,000 compared to $4,524,000 in the prior year quarter. Domestic segment EBITDA was $6,712,000 compared to $6,838,000 for the prior year quarter. Segment profitability was impacted during the period by lower manufacturing volumes across the laboratory construction portion of the business, offset by the addition of Nu Aire, Inc. ("Nu Aire"), who had a strong quarter. International Segment - International sales for the quarter were $14,872,000, an increase of 31.0% from sales of $11,355,000 in the prior year quarter. International segment net earnings were $641,000 compared to $356,000 in the prior year quarter. International segment EBITDA was $860,000 compared to $592,000 for the prior year quarter. International sales increased when compared to the prior year period due to the continued delivery of large projects that were booked in prior periods, a trend that continues from the Company's first quarter fiscal year 2026 results. Corporate Segment – Corporate segment pre-tax net loss was $2,515,000 for the quarter, as compared to a pre-tax net loss of $2,444,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($1,782,000) compared to corporate segment EBITDA of ($2,547,000) for the prior year quarter. Corporate segment EBITDA im...

STATESVILLE, N.C., Nov. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release its second quarter fiscal year 2026 financial results on Wednesday, December 10, 2025 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China. Learn more at the companies' websites, located at http://www.kewaunee.com and http://www.nuaire.com/. This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are int...